http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c08820aefb25704eea0323ad90d22499
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Jerónimo |
| name | Carmen Jerónimo |
| given-name | Carmen |
| organization-name | Cancer Biology & Epigenetics Group – Research Center CI-IPOP, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology & Molecular Immunology, Institute of Biomedical Sciences Abel Salazar – University of Porto (ICBAS-UP), Porto, Portugal Cancer Epigenetics & Biology Group, Research Center, Portuguese Oncology Institute-Porto, Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal Cancer Biology and Epigenetics Group—Research Center, Portuguese Oncology Institute, Porto Portugal; Department of Pathology and Molecular Immunology Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto Portugal Cancer Biology and Epigenetics Group; Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt. Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt. Portuguese Oncology Institute of Porto, Research Center-LAB 3, F Bdg, 1st floor, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt. Cancer Biology & Epigenetics Group Portuguese Oncology Institute‐Porto Porto Portugal; Department of Pathology and Molecular Immunology‐Biomedical Sciences Institute Abel Salazar (ICBAS) University of Porto Porto Portugal Cancer Biology & Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal Cancer Biology & Epigenetics Group, Research Center Portuguese Oncology Institute - Porto. Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS) - University of Porto, Porto, Portugal Cancer Biology & Epigenetics Group, Research Center of the Portuguese Oncology Institute-Porto; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto Cancer Epigenetics Group, Research Center, Portuguese Oncology Institute - Porto, Portugal; Department of Genetics, Portuguese Oncology Institute - Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal Cancer Biology & Epigenetics Group, Research Center (CI-IPOP) Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal; Department of Pathology and Molecular Immunology, ICBAS − School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal; Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal Authors' Affiliations: 1Cancer Epigenetics Group, and 2Department of Genetics, Portuguese Oncology Institute – Porto, Porto, Portugal; 3Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 4Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway; 5Department of Pathology, Portuguese Oncology Institute – Porto, Porto, Portugal; 6Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; 7Department of Urology, Portuguese Oncology Institute – Porto, Porto, Portugal; 8Faculty of Medicine, University of Oslo, Norway; and 9Cancer Genetics Group, Research Center of the Portuguese Oncology Institute – Porto, Porto, Portugal; Authors' Affiliations: 1Cancer Epigenetics Group, and 2Department of Genetics, Portuguese Oncology Institute – Porto, Porto, Portugal; 3Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 4Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway; 5Department of Pathology, Portuguese Oncology Institute – Porto, Porto, Portugal; 6Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; 7Department of Urology, Portuguese Oncology Institute – Porto, Porto, Portugal; 8Faculty of Medicine, University of Oslo, Norway; and 9Cancer Genetics Group, Research Center of the Portuguese Oncology Institute – Porto, Porto, Portugal; Authors' Affiliations: 1Cancer Epigenetics Group, and 2Department of Genetics, Portuguese Oncology Institute – Porto, Porto, Portugal; 3Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 4Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway; 5Department of Pathology, Portuguese Oncology Institute – Porto, Porto, Portugal; 6Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; 7Department of Urology, Portuguese Oncology Institute – Porto, Porto, Portugal; 8Faculty of Medicine, University of Oslo, Norway; and 9Cancer Genetics Group, Research Center of the Portuguese Oncology Institute – Porto, Porto, Portugal Cancer Biology & Epigenetics Group - Research Center of Portuguese Oncology Institute – Porto (CI-IPOP), Porto, Portugal; Department of Pathology & Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS) - University of Porto, Portugal Department of Pathology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. carmenjeronimo@netc.jp Cancer Biology & Epigenetics Group, Research Center, Portuguese Oncology Institute of Porto, Porto, Portugal; Porto Comprehensive Cancer Center (PCCC), Porto, Portugal; Department of Pathology & Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-ICBAS, University of Porto, Porto, Portugal Authors' Affiliations: 1Cancer Epigenetics Group, Research Center of the Portuguese Oncology Institute-Porto; 2Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal; 3Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL); and 4Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain; Authors' Affiliations: 1Cancer Epigenetics Group, Research Center of the Portuguese Oncology Institute-Porto; 2Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal; 3Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL); and 4Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain Cancer Biology and Epigenetics Group – CI-IPOP, Portuguese Oncology Institute-Porto, Rua Dr. António Bernardino de Almeida, Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira, Porto, Portugal Cancer Biology & Epigenetics Group−Research Centre, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar−University of Porto (ICBAS-UP), 4050-313 Porto, Portugal Cancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal; Department of Pathology & Molecular Immunology, Institute of Biomedical Sciences Abel Salazar – University of Porto (ICBAS-UP), Porto, Portugal Department of Genetics, Portuguese Oncology Institute-Porto, 4200-072 Porto, Portugal. cjeronimo@hotmail.com Department of Genetics, Portuguese Oncology Institute—Porto, Rua Dr. Antonio Bernardino de Almeida, 4200-072 Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Largo Prof. Abel Salazar 2, 4099-003 Porto, Portugal; Fernando Pessoa University School of Health Sciences, Rua Carlos da Maia, 296, 4200-150, Porto, Portugal Genetics Department and Research Center, Portuguese Oncology Institute, 4200-072 Porto, Portugal;; Department of Pathology and Genetics, Biomedical Sciences Institute, University of Porto, 4200-072 Porto, Portugal; and Cancer Epigenetics Group, Research Center of the Portuguese Oncology Institute—Porto, Porto, Portugal.; Department of Genetics, Portuguese Oncology Institute—Porto, Porto, Portugal.; Department of Pathology and Molecular Immunology, ICBAS—Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal. Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal; Department of Pathology and Molecular Immunology; Institute of Biomedical Sciences Abel Salazar, University of Porto; Porto Portugal Cancer Biology & Epigenetics Group Portuguese Oncology Institute of Porto (IPOPorto) Porto Portugal; Department of Pathology and Molecular Immunology‐Biomedical Sciences Institute (ICBAS) University of Porto Porto Portugal Department of Pathology and Cancer Biology and Epigenetics Group—Research Center, Portuguese Oncology Institute of Porto/Porto Comprehensive Cancer Center Raquel Seruca, School of Medicine and Biomedical Sciences (ICBAS), University of Porto, 4050-513 Porto, Portugal Cancer Biology and Epigenetics Group Research Center of the Portuguese Oncology Institute ‐ Porto Porto Portugal; Department of Pathology and Molecular Immunology Institute of Biomedical Sciences Abel Salazar University of Porto Porto Portugal Cancer Biology & Epigenetics Group Research Center, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal Department of Otolaryngology–Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Genetics, Portuguese Oncology Institute—Porto, Porto, Portugal.; Fernando Pessoa University School of Health Sciences, Porto, Portugal. Cancer Biology and Epigenetics Group, Research Center of The Portuguese Oncology Institute of PortoPorto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of PortoPorto, Portugal. Abteilung für Pathologie, IPO-PORTO, Porto, Portugal; Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), Porto Cancer Biology and Epigenetics Group, IPO‐Porto Research Center (CI‐IPOP), Portuguese Oncology Institute of Porto (IPO‐Porto) Porto Portugal; Department of Pathology and Molecular Immunology Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto Porto Portugal Cancer Epigenetics & Biology Group, Research Center, Portuguese Oncology Institute of Porto; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI‐IPOP) Portuguese Oncology Institute of Porto (IPO Porto) Porto Portugal Cancer Biology & Epigenetics Group – Research Center Portuguese Oncology Institute – Porto (IPO‐Porto) Porto Portugal; Department of Pathology and Molecular Immunology Institute of Biomedical Sciences Abel Salazar (ICBAS) University of Porto Porto Portugal Cancer Biology & Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto, Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), Porto, Portugal; Department of Pathology & Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal Cancer Biology and Epigenetics Group - Research Center, Portuguese Oncology Institute – Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS) - University of Porto, Portugal Portuguese Oncology Institute, Department of Genetics, Portuguese Oncology Institute – Porto, Rua Dr Antonio Bernardino de Almeida, 4200-072 Porto, Portugal.; and Fernando Pessoa University School of Health Sciences, Rua Carlos da Maia, 296, 4200-150, Porto, Portugal. |
Incoming Links
Total number of triples: 181.